Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9P2P5

UPID:
HECW2_HUMAN

ALTERNATIVE NAMES:
HECT, C2 and WW domain-containing protein 2; HECT-type E3 ubiquitin transferase HECW2; NEDD4-like E3 ubiquitin-protein ligase 2

ALTERNATIVE UPACC:
Q9P2P5; B8ZZB4; Q17RT5; Q68DF8; Q9NPS9

BACKGROUND:
The E3 ubiquitin-protein ligase HECW2, known for its alternative names such as HECT-type E3 ubiquitin transferase HECW2, plays a critical role in the ubiquitination process of TP73, thereby influencing TP73's stability and transcriptional activity. This process is vital for the proper execution of cellular functions, including cell cycle progression and DNA damage response. Additionally, HECW2's involvement in regulating the mitotic metaphase/anaphase transition highlights its importance in cell division.

THERAPEUTIC SIGNIFICANCE:
Given its association with a severe neurodevelopmental disorder characterized by delayed development, epilepsy, and brain abnormalities, the study of E3 ubiquitin-protein ligase HECW2 holds promise for uncovering novel therapeutic avenues. The exploration of its functions and mechanisms may pave the way for breakthrough treatments for this and potentially other neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.